Engineering bioactive mineralized tumor cells for tumor immunotherapy
IntroductionWhole-cell tumor vaccines are advantageous because of their ability to induce a broad and multifaceted immune response through the presentation of a wide range of tumor antigens, thereby enhancing the ability of the immune system to recognize and target cancerous cells.MethodIn this stud...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1582490/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849738572989464576 |
|---|---|
| author | Zikun Shen Yan He Ren Mo Dan Shao |
| author_facet | Zikun Shen Yan He Ren Mo Dan Shao |
| author_sort | Zikun Shen |
| collection | DOAJ |
| description | IntroductionWhole-cell tumor vaccines are advantageous because of their ability to induce a broad and multifaceted immune response through the presentation of a wide range of tumor antigens, thereby enhancing the ability of the immune system to recognize and target cancerous cells.MethodIn this study, we present a multifunctional vaccine that consists of manganese-mineralized tumor cells and positively charged polymer-immobilized CpG. The Mn2+ and CpG released from the engineered vaccine facilitate the maturation of dendritic cells through the activation of the cGAS-STING and TLR9 pathways, respectively.ResultAs a consequence, the engineered vaccine derived from B16F10 cells exhibited a pronounced tumor-suppressive effect, reducing the tumor volume to approximately one-fifth of that in the control group, and significantly extending survival to day 30 in B16F10 tumor-bearing mice. This superior therapeutic outcome is associated with enhanced activation of dendritic cells, increased infiltration of NK and CD8+ T cells, and increased production of immune cytokines within the tumor microenvironment.DiscussionTogether, our study highlights the immense potential of engineering bioactive mineralized tumor cells to facilitate whole-cell tumor vaccine-based immunotherapy. |
| format | Article |
| id | doaj-art-83222d5ebb864463bc74ec91fef961f6 |
| institution | DOAJ |
| issn | 2296-4185 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj-art-83222d5ebb864463bc74ec91fef961f62025-08-20T03:06:31ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852025-04-011310.3389/fbioe.2025.15824901582490Engineering bioactive mineralized tumor cells for tumor immunotherapyZikun Shen0Yan He1Ren Mo2Dan Shao3School of Medicine, South China University of Technology, Guangzhou, Guangdong, ChinaSchool of Medicine, South China University of Technology, Guangzhou, Guangdong, ChinaDepartment of Urology, Inner Mongolia People’s Hospital, Inner Mongolia Urological Institute, Hohhot, Inner Mongolia, ChinaSchool of Medicine, South China University of Technology, Guangzhou, Guangdong, ChinaIntroductionWhole-cell tumor vaccines are advantageous because of their ability to induce a broad and multifaceted immune response through the presentation of a wide range of tumor antigens, thereby enhancing the ability of the immune system to recognize and target cancerous cells.MethodIn this study, we present a multifunctional vaccine that consists of manganese-mineralized tumor cells and positively charged polymer-immobilized CpG. The Mn2+ and CpG released from the engineered vaccine facilitate the maturation of dendritic cells through the activation of the cGAS-STING and TLR9 pathways, respectively.ResultAs a consequence, the engineered vaccine derived from B16F10 cells exhibited a pronounced tumor-suppressive effect, reducing the tumor volume to approximately one-fifth of that in the control group, and significantly extending survival to day 30 in B16F10 tumor-bearing mice. This superior therapeutic outcome is associated with enhanced activation of dendritic cells, increased infiltration of NK and CD8+ T cells, and increased production of immune cytokines within the tumor microenvironment.DiscussionTogether, our study highlights the immense potential of engineering bioactive mineralized tumor cells to facilitate whole-cell tumor vaccine-based immunotherapy.https://www.frontiersin.org/articles/10.3389/fbioe.2025.1582490/fullwhole-cell tumor vaccinesmineralizationbioactiveSTINGimmunotherapy |
| spellingShingle | Zikun Shen Yan He Ren Mo Dan Shao Engineering bioactive mineralized tumor cells for tumor immunotherapy Frontiers in Bioengineering and Biotechnology whole-cell tumor vaccines mineralization bioactive STING immunotherapy |
| title | Engineering bioactive mineralized tumor cells for tumor immunotherapy |
| title_full | Engineering bioactive mineralized tumor cells for tumor immunotherapy |
| title_fullStr | Engineering bioactive mineralized tumor cells for tumor immunotherapy |
| title_full_unstemmed | Engineering bioactive mineralized tumor cells for tumor immunotherapy |
| title_short | Engineering bioactive mineralized tumor cells for tumor immunotherapy |
| title_sort | engineering bioactive mineralized tumor cells for tumor immunotherapy |
| topic | whole-cell tumor vaccines mineralization bioactive STING immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1582490/full |
| work_keys_str_mv | AT zikunshen engineeringbioactivemineralizedtumorcellsfortumorimmunotherapy AT yanhe engineeringbioactivemineralizedtumorcellsfortumorimmunotherapy AT renmo engineeringbioactivemineralizedtumorcellsfortumorimmunotherapy AT danshao engineeringbioactivemineralizedtumorcellsfortumorimmunotherapy |